{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:50:58Z","timestamp":1793742658811,"version":"4.6.1"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100017599","name":"Major Science and Technology Projects of Zhejiang Province","doi-asserted-by":"crossref","award":["2012C13019-1"],"award-info":[{"award-number":["2012C13019-1"]}],"id":[{"id":"10.13039\/501100017599","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Program offered by the Health Bureau of Zhejiang Province","award":["2021RC043"],"award-info":[{"award-number":["2021RC043"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"crossref","award":["Y-pierrefabre202101-0126"],"award-info":[{"award-number":["Y-pierrefabre202101-0126"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-024-01705-7","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T06:39:30Z","timestamp":1735281570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer"],"prefix":"10.1007","volume":"15","author":[{"given":"Jia-yu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-yuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-ru","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-huan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"1705_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1705_CR2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21777","author":"LA Huppert","year":"2023","unstructured":"Huppert LA, Gumusay O, Idossa D, Rugo HS. Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023. https:\/\/doi.org\/10.3322\/caac.21777.","journal-title":"CA Cancer J Clin"},{"key":"1705_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288\u2013300. https:\/\/doi.org\/10.1001\/jama.2018.19323.","journal-title":"JAMA"},{"key":"1705_CR4","doi-asserted-by":"publisher","unstructured":"Breast cancer. Nat Rev Dis Primers 2019;5:67. https:\/\/doi.org\/10.1038\/s41572-019-0122-z.","DOI":"10.1038\/s41572-019-0122-z"},{"key":"1705_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan J-J, Bian X-W, Yu S-C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5.","journal-title":"Breast Cancer Res"},{"key":"1705_CR6","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1158\/1055-9965.EPI-12-0474","volume":"21","author":"R Haque","year":"2012","unstructured":"Haque R, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012;21:1848\u201355. https:\/\/doi.org\/10.1158\/1055-9965.EPI-12-0474.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1705_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1001\/jama.2018.20751","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks AG, Winer EP. Breast cancer treatment. JAMA. 2019;321:316\u2013316. https:\/\/doi.org\/10.1001\/jama.2018.20751.","journal-title":"JAMA"},{"issue":"4","key":"1705_CR8","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.3390\/ijms23042288","volume":"23","author":"KH Lau","year":"2022","unstructured":"Lau KH, Tan AM, Shi Y. New and emerging targeted therapies for advanced breast cancer. Int J Mol Sci. 2022;23(4):2288.","journal-title":"Int J Mol Sci"},{"key":"1705_CR9","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1002\/cncr.33102","volume":"126","author":"S Kunte","year":"2020","unstructured":"Kunte S, Abraham J, Montero AJ. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer. 2020;126:4278\u201388. https:\/\/doi.org\/10.1002\/cncr.33102.","journal-title":"Cancer"},{"key":"1705_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton ET. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22:101\u201326. https:\/\/doi.org\/10.1038\/s41573-022-00579-0.","journal-title":"Nat Rev Drug Discov"},{"key":"1705_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707\u201312. https:\/\/doi.org\/10.1126\/science.2470152.","journal-title":"Science"},{"key":"1705_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"D-Y Oh","year":"2020","unstructured":"Oh D-Y, Bang Y-J. HER2-targeted therapies \u2014 a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33\u201348. https:\/\/doi.org\/10.1038\/s41571-019-0268-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1705_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Signal Transduct Target Ther"},{"key":"1705_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105. https:\/\/doi.org\/10.1186\/s12943-023-01805-y.","journal-title":"Mol Cancer"},{"issue":"10","key":"1705_CR15","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3390\/cancers14102569","volume":"14","author":"B Smolarz","year":"2022","unstructured":"Smolarz B, Nowak AZ, Romanowicz H. Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature). Cancers. 2022;14(10):2569.","journal-title":"Cancers"},{"issue":"7","key":"1705_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/cancers11071033","volume":"11","author":"G Planes-Laine","year":"2019","unstructured":"Planes-Laine G, et al. PD-1\/PD-L1 targeting in breast cancer: the first clinical evidences are emerging\u2014a literature review. Cancers. 2019;11(7):1033.","journal-title":"Cancers"},{"key":"1705_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","volume":"80","author":"SJ Keam","year":"2020","unstructured":"Keam SJ. Trastuzumab deruxtecan: first approval. Drugs. 2020;80:501\u20138. https:\/\/doi.org\/10.1007\/s40265-020-01281-4.","journal-title":"Drugs"},{"issue":"9","key":"1705_CR18","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.3390\/ijms22094774","volume":"22","author":"A Indini","year":"2021","unstructured":"Indini A, Rijavec E, Grossi F. Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors. Int J Mol Sci. 2021;22(9):4774. https:\/\/doi.org\/10.3390\/ijms22094774.","journal-title":"Int J Mol Sci"},{"key":"1705_CR19","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/2159-8290.Cd-nb2022-0061","volume":"12","author":"American Association for Cancer Research","year":"2022","unstructured":"American Association for Cancer Research. SG improves OS in HR+\/HER2\u2212 breast cancer. Cancer Discov. 2022;12:2714\u20135. https:\/\/doi.org\/10.1158\/2159-8290.Cd-nb2022-0061.","journal-title":"Cancer Discov"},{"key":"1705_CR20","doi-asserted-by":"publisher","first-page":"32242","DOI":"10.1074\/jbc.M110.160820","volume":"285","author":"H Yang","year":"2010","unstructured":"Yang H, Ganguly A, Cabral F. Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. J Biol Chem. 2010;285:32242\u201350. https:\/\/doi.org\/10.1074\/jbc.M110.160820.","journal-title":"J Biol Chem"},{"key":"1705_CR21","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111:538\u201349. https:\/\/doi.org\/10.1093\/jnci\/djz035.","journal-title":"J Natl Cancer Inst"},{"key":"1705_CR22","doi-asserted-by":"publisher","first-page":"107917","DOI":"10.1016\/j.pharmthera.2021.107917","volume":"229","author":"Y Jin","year":"2022","unstructured":"Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ. Stepping forward in antibody-drug conjugate development. Pharmacol Ther. 2022;229:107917. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107917.","journal-title":"Pharmacol Ther"},{"key":"1705_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody-drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18:3\u201319. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0582.","journal-title":"Mol Cancer Res"},{"key":"1705_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jcp.28967","volume":"235","author":"S Yaghoubi","year":"2020","unstructured":"Yaghoubi S, et al. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy. J Cell Physiol. 2020;235:31\u201364. https:\/\/doi.org\/10.1002\/jcp.28967.","journal-title":"J Cell Physiol"},{"key":"1705_CR25","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117:1736\u201342. https:\/\/doi.org\/10.1038\/bjc.2017.367.","journal-title":"Br J Cancer"},{"key":"1705_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nri2545","volume":"9","author":"DR Green","year":"2009","unstructured":"Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009;9:353\u201363. https:\/\/doi.org\/10.1038\/nri2545.","journal-title":"Nat Rev Immunol"},{"key":"1705_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/CCO.0b013e32831bc375","volume":"21","author":"O Kepp","year":"2009","unstructured":"Kepp O, Tesniere A, Zitvogel L, Kroemer G. The immunogenicity of tumor cell death. Curr Opin Oncol. 2009;21:71\u20136. https:\/\/doi.org\/10.1097\/CCO.0b013e32831bc375.","journal-title":"Curr Opin Oncol"},{"key":"1705_CR28","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nri.2016.153","volume":"17","author":"S Nagata","year":"2017","unstructured":"Nagata S, Tanaka MP. Programmed cell death and the immune system. Nat Rev Immunol. 2017;17:333\u201340. https:\/\/doi.org\/10.1038\/nri.2016.153.","journal-title":"Nat Rev Immunol"},{"key":"1705_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54\u201361. https:\/\/doi.org\/10.1038\/nm1523.","journal-title":"Nat Med"},{"key":"1705_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nbt0207-192","volume":"25","author":"C Clarke","year":"2007","unstructured":"Clarke C, Smyth MJ. Calreticulin exposure increases cancer immunogenicity. Nat Biotechnol. 2007;25:192\u20133. https:\/\/doi.org\/10.1038\/nbt0207-192.","journal-title":"Nat Biotechnol"},{"key":"1705_CR31","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/emboj.2011.497","volume":"31","author":"AD Garg","year":"2012","unstructured":"Garg AD, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012;31:1062\u201379. https:\/\/doi.org\/10.1038\/emboj.2011.497.","journal-title":"EMBO J"},{"key":"1705_CR32","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/0008-5472.Can-16-2854","volume":"77","author":"J Rios-Doria","year":"2017","unstructured":"Rios-Doria J, et al. Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies. Cancer Res. 2017;77:2686\u201398. https:\/\/doi.org\/10.1158\/0008-5472.Can-16-2854.","journal-title":"Cancer Res"},{"key":"1705_CR33","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.Mct-17-0749","volume":"17","author":"TN Iwata","year":"2018","unstructured":"Iwata TN, et al. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 2018;17:1494\u2013503. https:\/\/doi.org\/10.1158\/1535-7163.Mct-17-0749.","journal-title":"Mol Cancer Ther"},{"key":"1705_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000860","author":"F Zammarchi","year":"2020","unstructured":"Zammarchi F, et al. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000860.","journal-title":"J Immunother Cancer"},{"key":"1705_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier E, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44\u20139. https:\/\/doi.org\/10.1126\/science.1198687.","journal-title":"Science"},{"key":"1705_CR36","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3390\/biomedicines12071491","volume":"12","author":"S Nucera","year":"2024","unstructured":"Nucera S, Conti C, Martorana F, Wilson B, Genta S. Antibody-drug conjugates to promote immune surveillance: lessons learned from breast cancer. Biomedicines. 2024;12:1491.","journal-title":"Biomedicines"},{"key":"1705_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","volume":"7","author":"L D\u2019Amico","year":"2019","unstructured":"D\u2019Amico L, et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer. 2019;7:16. https:\/\/doi.org\/10.1186\/s40425-018-0464-1.","journal-title":"J Immunother Cancer"},{"key":"1705_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/DDDT.S4378","volume":"3","author":"A Natsume","year":"2009","unstructured":"Natsume A, Niwa R, Satoh M. Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Design Dev Ther. 2009;3:7\u201316. https:\/\/doi.org\/10.2147\/DDDT.S4378.","journal-title":"Drug Design Dev Ther"},{"key":"1705_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071571","author":"J Radocha","year":"2021","unstructured":"Radocha J, van de Donk N, Weisel K. Monoclonal antibodies and antibody drug conjugates in multiple myeloma. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13071571.","journal-title":"Cancers"},{"key":"1705_CR40","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128\u201338. https:\/\/doi.org\/10.1182\/blood-2013-10-535088.","journal-title":"Blood"},{"key":"1705_CR41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","volume":"200","author":"PK Mahalingaiah","year":"2019","unstructured":"Mahalingaiah PK, et al. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther. 2019;200:110\u201325. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.04.008.","journal-title":"Pharmacol Ther"},{"key":"1705_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204764","author":"U Hafeez","year":"2020","unstructured":"Hafeez U, Parakh S, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25204764.","journal-title":"Molecules"},{"key":"1705_CR43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy H. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs. 2016;8:659\u201371. https:\/\/doi.org\/10.1080\/19420862.2016.1156829.","journal-title":"MAbs"},{"key":"1705_CR44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/cm9.0000000000001932","volume":"135","author":"L Li","year":"2021","unstructured":"Li L, et al. Antibody-drug conjugates in HER2-positive breast cancer. Chin Med J. 2021;135:261\u20137. https:\/\/doi.org\/10.1097\/cm9.0000000000001932.","journal-title":"Chin Med J"},{"key":"1705_CR45","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40264-018-0775-7","volume":"42","author":"A Wolska-Washer","year":"2019","unstructured":"Wolska-Washer A, Robak T. Safety and tolerability of antibody-drug conjugates in cancer. Drug Saf. 2019;42:295\u2013314. https:\/\/doi.org\/10.1007\/s40264-018-0775-7.","journal-title":"Drug Saf"},{"issue":"4","key":"1705_CR46","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/ijms17040561","volume":"17","author":"J Lu","year":"2016","unstructured":"Lu J, Jiang F, Lu A, Zhang G. Linkers having a crucial role in antibody\u2013drug conjugates. Int J Mol Sci. 2016;17(4):561.","journal-title":"Int J Mol Sci"},{"key":"1705_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33\u201346. https:\/\/doi.org\/10.1007\/s13238-016-0323-0.","journal-title":"Protein Cell"},{"key":"1705_CR48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","volume":"36","author":"JC Masters","year":"2018","unstructured":"Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs. 2018;36:121\u201335. https:\/\/doi.org\/10.1007\/s10637-017-0520-6.","journal-title":"Invest New Drugs"},{"key":"1705_CR49","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1208\/s12248-015-9790-0","volume":"17","author":"MJ Hinrichs","year":"2015","unstructured":"Hinrichs MJ, Dixit R. Antibody drug conjugates: nonclinical safety considerations. AAPS J. 2015;17:1055\u201364. https:\/\/doi.org\/10.1208\/s12248-015-9790-0.","journal-title":"AAPS J"},{"key":"1705_CR50","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","volume":"107","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039\u201346. https:\/\/doi.org\/10.1111\/cas.12966.","journal-title":"Cancer Sci"},{"key":"1705_CR51","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.1158\/1078-0432.CCR-16-2862","volume":"23","author":"G Menderes","year":"2017","unstructured":"Menderes G, et al. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2\/Neu expression. Clin Cancer Res. 2017;23:5836\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2862.","journal-title":"Clin Cancer Res"},{"key":"1705_CR52","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.Ccr-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097\u2013108. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2822.","journal-title":"Clin Cancer Res"},{"key":"1705_CR53","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.yrtph.2015.01.014","volume":"71","author":"H Saber","year":"2015","unstructured":"Saber H, Leighton JK. An FDA oncology analysis of antibody-drug conjugates. Regulat Toxicol Pharmacol. 2015;71:444\u201352. https:\/\/doi.org\/10.1016\/j.yrtph.2015.01.014.","journal-title":"Regulat Toxicol Pharmacol"},{"key":"1705_CR54","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.tips.2021.07.005","volume":"42","author":"I Nessler","year":"2021","unstructured":"Nessler I, Menezes B, Thurber GM. Key metrics to expanding the pipeline of successful antibody-drug conjugates. Trends Pharmacol Sci. 2021;42:803\u201312. https:\/\/doi.org\/10.1016\/j.tips.2021.07.005.","journal-title":"Trends Pharmacol Sci"},{"key":"1705_CR55","first-page":"4750","volume":"61","author":"GP Adams","year":"2001","unstructured":"Adams GP, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Can Res. 2001;61:4750\u20135.","journal-title":"Can Res"},{"key":"1705_CR56","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/0008-5472.Can-17-1638","volume":"78","author":"C Cilliers","year":"2018","unstructured":"Cilliers C, Menezes B, Nessler I, Linderman J, Thurber GM. Improved tumor penetration and single-cell targeting of antibody-drug conjugates increases anticancer efficacy and host survival. Can Res. 2018;78:758\u201368. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-1638.","journal-title":"Can Res"},{"key":"1705_CR57","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"key":"1705_CR58","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","volume":"20","author":"U Banerji","year":"2019","unstructured":"Banerji U, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20:1124\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(19)30328-6.","journal-title":"Lancet Oncol"},{"key":"1705_CR59","doi-asserted-by":"publisher","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-22-0456","volume":"28","author":"J Zhang","year":"2022","unstructured":"Zhang J, et al. Phase I trial of a novel anti-HER2 antibody-drug conjugate, ARX788, for the treatment of HER2-positive metastatic breast cancer. Clin Cancer Res. 2022;28:4212\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0456.","journal-title":"Clin Cancer Res"},{"key":"1705_CR60","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS20-PD3-07","author":"E Hamilton","year":"2021","unstructured":"Hamilton E, et al. Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study. Cancer Res. 2021. https:\/\/doi.org\/10.1158\/1538-7445.SABCS20-PD3-07.","journal-title":"Cancer Res"},{"issue":"1","key":"1705_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-023-01509-2","volume":"17","author":"Q Wei","year":"2024","unstructured":"Wei Q, et al. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024;17(1):1. https:\/\/doi.org\/10.1186\/s13045-023-01509-2.","journal-title":"J Hematol Oncol"},{"key":"1705_CR62","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/annonc\/mdw157","volume":"27","author":"M Martin","year":"2016","unstructured":"Martin M, et al. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib\/IIa study. Ann Oncol. 2016;27:1249\u201356. https:\/\/doi.org\/10.1093\/annonc\/mdw157.","journal-title":"Ann Oncol"},{"key":"1705_CR63","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.jtho.2022.07.152","volume":"17","author":"B Levy","year":"2022","unstructured":"Levy B, et al. MA13.07 TROPION-Lung 02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. J Thorac Oncol. 2022;17:S91. https:\/\/doi.org\/10.1016\/j.jtho.2022.07.152.","journal-title":"J Thorac Oncol"},{"key":"1705_CR64","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.2022.40.4_suppl.295","volume":"40","author":"YY Janjigian","year":"2022","unstructured":"Janjigian YY, et al. Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced\/metastatic HER2+ gastric cancer (GC)\/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03. J Clin Oncol. 2022;40:295\u2013295. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.295.","journal-title":"J Clin Oncol"},{"key":"1705_CR65","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2021.04.011","volume":"32","author":"EP Mamounas","year":"2021","unstructured":"Mamounas EP, et al. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. Ann Oncol. 2021;32:1005\u201314. https:\/\/doi.org\/10.1016\/j.annonc.2021.04.011.","journal-title":"Ann Oncol"},{"key":"1705_CR66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS623","author":"SA Hurvitz","year":"2022","unstructured":"Hurvitz SA, et al. TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS623.","journal-title":"J Clin Oncol"},{"key":"1705_CR67","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.annonc.2022.03.185","volume":"33","author":"P Schmid","year":"2022","unstructured":"Schmid P, et al. 166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): initial results from BEGONIA, a phase Ib\/II study. Ann Oncol. 2022;33:199. https:\/\/doi.org\/10.1016\/j.annonc.2022.03.185.","journal-title":"Ann Oncol"},{"key":"1705_CR68","doi-asserted-by":"publisher","first-page":"8592","DOI":"10.1200\/JCO.2024.42.16_suppl.8592","volume":"42","author":"JD Patel","year":"2024","unstructured":"Patel JD, et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 \u2265 50%: cohort A of EVOKE-02. J Clin Oncol. 2024;42:8592\u20138592. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8592.","journal-title":"J Clin Oncol"},{"key":"1705_CR69","doi-asserted-by":"publisher","first-page":"103960","DOI":"10.1016\/j.critrevonc.2023.103960","volume":"184","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, et al. Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2023;184:103960. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103960.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1705_CR70","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/s0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401:1773\u201385. https:\/\/doi.org\/10.1016\/s0140-6736(23)00725-0.","journal-title":"Lancet"},{"key":"1705_CR71","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","volume":"7","author":"P Tarantino","year":"2021","unstructured":"Tarantino P, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 2021;7:1873\u201381. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3595.","journal-title":"JAMA Oncol"},{"key":"1705_CR72","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2013.33.e103","author":"R Mathur","year":"2013","unstructured":"Mathur R, Weiner GJ. Picking the optimal target for antibody-drug conjugates. Am Soc Clin Oncol Educ Book. 2013. https:\/\/doi.org\/10.14694\/EdBook_AM.2013.33.e103.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"1705_CR73","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4161\/mabs.22854","volume":"5","author":"M Ritchie","year":"2013","unstructured":"Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. 2013;5(1):13\u201321. https:\/\/doi.org\/10.4161\/mabs.22854.","journal-title":"MAbs"},{"key":"1705_CR74","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.yrtph.2015.01.014","volume":"71","author":"H Saber","year":"2015","unstructured":"Saber H, Leighton JK. An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol. 2015;71:444\u201352. https:\/\/doi.org\/10.1016\/j.yrtph.2015.01.014.","journal-title":"Regul Toxicol Pharmacol"},{"key":"1705_CR75","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa NS. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315\u201337. https:\/\/doi.org\/10.1038\/nrd.2016.268.","journal-title":"Nat Rev Drug Discov"},{"key":"1705_CR76","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1111\/cas.14686","volume":"111","author":"K Kumagai","year":"2020","unstructured":"Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020;111:4636\u201345. https:\/\/doi.org\/10.1111\/cas.14686.","journal-title":"Cancer Sci"},{"key":"1705_CR77","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1158\/1535-7163.Mct-16-0710","volume":"16","author":"H Zhao","year":"2017","unstructured":"Zhao H, et al. Inhibition of megakaryocyte differentiation by antibody-drug conjugates (ADCs) is mediated by macropinocytosis: implications for ADC-induced thrombocytopenia. Mol Cancer Ther. 2017;16:1877\u201386. https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0710.","journal-title":"Mol Cancer Ther"},{"key":"1705_CR78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","volume":"39","author":"M Aoyama","year":"2022","unstructured":"Aoyama M, Tada M, Yokoo H, Demizu Y, Ishii-Watabe A. Fc\u03b3 receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates. Pharm Res. 2022;39:89\u2013103. https:\/\/doi.org\/10.1007\/s11095-021-03158-x.","journal-title":"Pharm Res"},{"key":"1705_CR79","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s11095-014-1541-x","volume":"32","author":"M Ahmadi","year":"2015","unstructured":"Ahmadi M, et al. Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm Res. 2015;32:1383\u201394. https:\/\/doi.org\/10.1007\/s11095-014-1541-x.","journal-title":"Pharm Res"},{"key":"1705_CR80","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.xphs.2019.10.046","volume":"109","author":"M Tada","year":"2020","unstructured":"Tada M, Aoyama M, Ishii-Watabe A. Fc\u03b3 receptor activation by human monoclonal antibody aggregates. J Pharm Sci. 2020;109:576\u201383. https:\/\/doi.org\/10.1016\/j.xphs.2019.10.046.","journal-title":"J Pharm Sci"},{"issue":"3","key":"1705_CR81","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers. 2023;15(3):713.","journal-title":"Cancers"},{"key":"1705_CR82","doi-asserted-by":"publisher","first-page":"e0223264","DOI":"10.1371\/journal.pone.0223264","volume":"14","author":"CW Bruggeman","year":"2019","unstructured":"Bruggeman CW, et al. Tissue-specific expression of IgG receptors by human macrophages ex vivo. PLoS ONE. 2019;14:e0223264. https:\/\/doi.org\/10.1371\/journal.pone.0223264.","journal-title":"PLoS ONE"},{"key":"1705_CR83","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.immuni.2022.08.010","volume":"55","author":"H Aegerter","year":"2022","unstructured":"Aegerter H, Lambrecht BN, Jakubzick CV. Biology of lung macrophages in health and disease. Immunity. 2022;55:1564\u201380. https:\/\/doi.org\/10.1016\/j.immuni.2022.08.010.","journal-title":"Immunity"},{"key":"1705_CR84","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1165\/rcmb.2016-0122OC","volume":"55","author":"RF Silver","year":"2016","unstructured":"Silver RF, et al. Diversity of human and macaque airway immune cells at baseline and during tuberculosis infection. Am J Respir Cell Mol Biol. 2016;55:899\u2013908. https:\/\/doi.org\/10.1165\/rcmb.2016-0122OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1705_CR85","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jim.2011.09.013","volume":"375","author":"KE Barletta","year":"2012","unstructured":"Barletta KE, et al. Leukocyte compartments in the mouse lung: distinguishing between marginated, interstitial, and alveolar cells in response to injury. J Immunol Methods. 2012;375:100\u201310. https:\/\/doi.org\/10.1016\/j.jim.2011.09.013.","journal-title":"J Immunol Methods"},{"key":"1705_CR86","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/ni.3005","volume":"15","author":"C Schneider","year":"2014","unstructured":"Schneider C, et al. Induction of the nuclear receptor PPAR-\u03b3 by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. Nat Immunol. 2014;15:1026\u201337. https:\/\/doi.org\/10.1038\/ni.3005.","journal-title":"Nat Immunol"},{"key":"1705_CR87","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.immuni.2017.10.006","volume":"47","author":"AW Roberts","year":"2017","unstructured":"Roberts AW, et al. Tissue-resident macrophages are locally programmed for silent clearance of apoptotic cells. Immunity. 2017;47:913-927.e916. https:\/\/doi.org\/10.1016\/j.immuni.2017.10.006.","journal-title":"Immunity"},{"key":"1705_CR88","doi-asserted-by":"publisher","first-page":"2006220","DOI":"10.1002\/adfm.202006220","volume":"31","author":"X Zhou","year":"2021","unstructured":"Zhou X, Liu X, Huang L. Macrophage-mediated tumor cell phagocytosis: opportunity for nanomedicine intervention. Adv Funct Mater. 2021;31:2006220. https:\/\/doi.org\/10.1002\/adfm.202006220.","journal-title":"Adv Funct Mater"},{"key":"1705_CR89","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nature01451","volume":"422","author":"SD Conner","year":"2003","unstructured":"Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003;422:37\u201344. https:\/\/doi.org\/10.1038\/nature01451.","journal-title":"Nature"},{"key":"1705_CR90","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2174\/138920009789895499","volume":"10","author":"JH Lin","year":"2009","unstructured":"Lin JH. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metab. 2009;10:661\u201391. https:\/\/doi.org\/10.2174\/138920009789895499.","journal-title":"Curr Drug Metab"},{"key":"1705_CR91","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2174\/1570161043385736","volume":"2","author":"S Muro","year":"2004","unstructured":"Muro S, Koval M, Muzykantov V. Endothelial endocytic pathways: gates for vascular drug delivery. Curr Vasc Pharmacol. 2004;2:281\u201399. https:\/\/doi.org\/10.2174\/1570161043385736.","journal-title":"Curr Vasc Pharmacol"},{"key":"1705_CR92","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1146\/annurev.biochem.78.081307.110540","volume":"78","author":"GJ Doherty","year":"2009","unstructured":"Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009;78:857\u2013902. https:\/\/doi.org\/10.1146\/annurev.biochem.78.081307.110540.","journal-title":"Annu Rev Biochem"},{"key":"1705_CR93","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-24-0267","author":"S Koganemaru","year":"2024","unstructured":"Koganemaru S, et al. Potential mechanisms of interstitial lung disease induced by antibody-drug conjugates based on quantitative analysis of drug distribution. Mol Cancer Ther. 2024. https:\/\/doi.org\/10.1158\/1535-7163.Mct-24-0267.","journal-title":"Mol Cancer Ther"},{"key":"1705_CR94","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas dermo-sifiliograficas. 2021;112:90\u20132. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009.","journal-title":"Actas dermo-sifiliograficas"},{"key":"1705_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7100356","author":"S Skeoch","year":"2018","unstructured":"Skeoch S, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018. https:\/\/doi.org\/10.3390\/jcm7100356.","journal-title":"J Clin Med"},{"key":"1705_CR96","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","volume":"82","author":"Z Abuhelwa","year":"2022","unstructured":"Abuhelwa Z, Alloghbi A, Alqahtani A, Nagasaka M. Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review. Drugs. 2022;82:979\u201387. https:\/\/doi.org\/10.1007\/s40265-022-01736-w.","journal-title":"Drugs"},{"key":"1705_CR97","doi-asserted-by":"publisher","first-page":"241","DOI":"10.19401\/j.cnki.1007-3639.2021.04.001","volume":"31","author":"Z Jian","year":"2021","unstructured":"Jian Z, et al. criteria for the management of targeted drug-induced interstitial lung disease in solid tumors. China Oncol. 2021;31:241\u20139. https:\/\/doi.org\/10.19401\/j.cnki.1007-3639.2021.04.001.","journal-title":"China Oncol"},{"key":"1705_CR98","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1093\/oncolo\/oyac107","volume":"27","author":"A Bardia","year":"2022","unstructured":"Bardia A, et al. Clinical practices and institutional protocols on prophylaxis, monitoring, and management of selected adverse events associated with trastuzumab deruxtecan. Oncologist. 2022;27:637\u201345. https:\/\/doi.org\/10.1093\/oncolo\/oyac107.","journal-title":"Oncologist"},{"key":"1705_CR99","unstructured":"\u4e2d\u56fd\u533b\u5e08\u534f\u4f1a\u80bf\u7624\u533b\u5e08\u5206\u4f1a\u4e73\u817a\u764c\u5b66\u7ec4 & \u4e2d\u56fd\u6297\u764c\u534f\u4f1a\u56fd\u9645\u533b\u7597\u4ea4\u6d41\u5206\u4f1a. \u4e2d\u56fd\u4e73\u817a\u764c\u6297\u4f53\u836f\u7269\u5076\u8054\u7269\u5b89\u5168\u6027\u7ba1\u7406\u4e13\u5bb6\u5171\u8bc6. \u4e2d\u534e\u80bf\u7624\u6742\u5fd7 2022;44:913\u201327."},{"key":"1705_CR100","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1148\/radiol.2021203427","volume":"298","author":"T Johkoh","year":"2021","unstructured":"Johkoh T, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Radiology. 2021;298:550\u201366. https:\/\/doi.org\/10.1148\/radiol.2021203427.","journal-title":"Radiology"},{"key":"1705_CR101","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1200\/jco.2014.32.15_suppl.626","volume":"32","author":"G Verheijden","year":"2014","unstructured":"Verheijden G, et al. Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC). J Clin Oncol. 2014;32:626\u2013626. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.626.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1705_CR102","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.annonc.2021.08.2088","volume":"32","author":"CS Manich","year":"2021","unstructured":"Manich CS, et al. LBA15 Primary outcome of the phase III SYD985.002\/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician\u2019s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol. 2021;32(5):1288\u20139.","journal-title":"Ann Oncol"},{"key":"1705_CR103","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/00005382-199101000-00008","volume":"6","author":"JE Kuhlman","year":"1991","unstructured":"Kuhlman JE. The role of chest computed tomography in the diagnosis of drug-related reactions. J Thorac Imaging. 1991;6:52\u201361. https:\/\/doi.org\/10.1097\/00005382-199101000-00008.","journal-title":"J Thorac Imaging"},{"key":"1705_CR104","doi-asserted-by":"publisher","first-page":"e2300391","DOI":"10.1200\/PO.23.00391","volume":"7","author":"M Nishino","year":"2023","unstructured":"Nishino M, et al. Trastuzumab deruxtecan-related interstitial lung disease\/pneumonitis: computed tomography imaging patterns to guide diagnosis and management. JCO Precis Oncol. 2023;7:e2300391. https:\/\/doi.org\/10.1200\/PO.23.00391.","journal-title":"JCO Precis Oncol"},{"key":"1705_CR105","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/mcp.0000000000000847","volume":"28","author":"K Chugh","year":"2022","unstructured":"Chugh K, Jatwani S. Transbronchial biopsy vs bronchoalveolar lavage in interstitial lung disease. Curr Opin Pulmonary Med. 2022;28:3\u20138. https:\/\/doi.org\/10.1097\/mcp.0000000000000847.","journal-title":"Curr Opin Pulmonary Med"},{"key":"1705_CR106","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0272-5231(03)00143-6","volume":"25","author":"U Costabel","year":"2004","unstructured":"Costabel U, Uzaslan E, Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med. 2004;25:25\u201335. https:\/\/doi.org\/10.1016\/S0272-5231(03)00143-6.","journal-title":"Clin Chest Med"},{"key":"1705_CR107","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1164\/rccm.201508-1632OC","volume":"193","author":"JP Hutchinson","year":"2016","unstructured":"Hutchinson JP, Fogarty AW, McKeever TM, Hubbard RB. In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States 2000 to 2011. Am J Respir Crit Care Med. 2016;193:1161\u20137. https:\/\/doi.org\/10.1164\/rccm.201508-1632OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"1705_CR108","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.3390\/jcm11133835","volume":"11","author":"H Yamakawa","year":"2022","unstructured":"Yamakawa H, et al. Anti-inflammatory and\/or anti-fibrotic treatment of MPO-ANCA-positive interstitial lung disease: a short review. J Clin Med. 2022;11(13):3835. https:\/\/doi.org\/10.3390\/jcm11133835.","journal-title":"J Clin Med"},{"key":"1705_CR109","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00408-022-00532-3","volume":"200","author":"S Yang","year":"2022","unstructured":"Yang S, et al. Serum oncomarkers in patients with MPO-ANCA-positive vasculitis: diagnostic and prognostic predictive values for interstitial lung disease. Lung. 2022;200:331\u20138. https:\/\/doi.org\/10.1007\/s00408-022-00532-3.","journal-title":"Lung"},{"key":"1705_CR110","doi-asserted-by":"publisher","first-page":"745233","DOI":"10.3389\/fimmu.2021.745233","volume":"12","author":"T Zhang","year":"2021","unstructured":"Zhang T, Shen P, Duan C, Gao L. KL-6 as an immunological biomarker predicts the severity, progression, acute exacerbation, and poor outcomes of interstitial lung disease: a systematic review and meta-analysis. Front Immunol. 2021;12:745233. https:\/\/doi.org\/10.3389\/fimmu.2021.745233.","journal-title":"Front Immunol"},{"key":"1705_CR111","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1378\/chest.108.2.311","volume":"108","author":"J Kobayashi","year":"1995","unstructured":"Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. Chest. 1995;108:311\u20135. https:\/\/doi.org\/10.1378\/chest.108.2.311.","journal-title":"Chest"},{"key":"1705_CR112","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1136\/thorax.58.10.872","volume":"58","author":"H Ohnishi","year":"2003","unstructured":"Ohnishi H, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003;58:872\u20135. https:\/\/doi.org\/10.1136\/thorax.58.10.872.","journal-title":"Thorax"},{"key":"1705_CR113","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","volume":"183","author":"MD Hackshaw","year":"2020","unstructured":"Hackshaw MD, et al. Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;183:23\u201339. https:\/\/doi.org\/10.1007\/s10549-020-05754-8.","journal-title":"Breast Cancer Res Treat"},{"key":"1705_CR114","doi-asserted-by":"publisher","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","volume":"106","author":"SM Swain","year":"2022","unstructured":"Swain SM, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treatment Rev. 2022;106:102378. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102378.","journal-title":"Cancer Treatment Rev"},{"key":"1705_CR115","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/17425255.2022.2162383","volume":"18","author":"WP Yong","year":"2022","unstructured":"Yong WP, et al. Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody\u2013drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. Expert Opin Drug Metab Toxicol. 2022;18:805\u201315. https:\/\/doi.org\/10.1080\/17425255.2022.2162383.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1705_CR116","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1002\/cncr.35475","volume":"130","author":"C Xu","year":"2024","unstructured":"Xu C, et al. Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease\/pneumonitis: an expert consensus in China. Cancer. 2024;130:3054\u201366. https:\/\/doi.org\/10.1002\/cncr.35475.","journal-title":"Cancer"},{"key":"1705_CR117","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med"},{"key":"1705_CR118","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/s1470-2045(17)30313-3","volume":"18","author":"IE Krop","year":"2017","unstructured":"Krop IE, et al. Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18:743\u201354. https:\/\/doi.org\/10.1016\/s1470-2045(17)30313-3.","journal-title":"Lancet Oncol"},{"key":"1705_CR119","doi-asserted-by":"publisher","first-page":"100561","DOI":"10.1016\/j.esmoop.2022.100561","volume":"7","author":"R Wuerstlein","year":"2022","unstructured":"Wuerstlein R, et al. Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer. ESMO Open. 2022;7:100561. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100561.","journal-title":"ESMO Open"},{"key":"1705_CR120","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1002\/cncr.27622","volume":"118","author":"M Beeram","year":"2012","unstructured":"Beeram M, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer. 2012;118:5733\u201340. https:\/\/doi.org\/10.1002\/cncr.27622.","journal-title":"Cancer"},{"key":"1705_CR121","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401:105\u201317. https:\/\/doi.org\/10.1016\/s0140-6736(22)02420-5.","journal-title":"Lancet"},{"key":"1705_CR122","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"1705_CR123","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1158\/2159-8290.Cd-19-1014","volume":"10","author":"J Tsurutani","year":"2020","unstructured":"Tsurutani J, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov. 2020;10:688\u2013701. https:\/\/doi.org\/10.1158\/2159-8290.Cd-19-1014.","journal-title":"Cancer Discov"},{"key":"1705_CR124","doi-asserted-by":"publisher","first-page":"LBA3000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","volume":"41","author":"F Meric-Bernstam","year":"2023","unstructured":"Meric-Bernstam F, et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. J Clin Oncol. 2023;41:LBA3000. https:\/\/doi.org\/10.1200\/JCO.2023.41.17_suppl.LBA3000.","journal-title":"J Clin Oncol"},{"key":"1705_CR125","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","volume":"24","author":"Y Xu","year":"2021","unstructured":"Xu Y, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24:913\u201325. https:\/\/doi.org\/10.1007\/s10120-021-01168-7.","journal-title":"Gastric Cancer"},{"key":"1705_CR126","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-0456","author":"J Zhang","year":"2022","unstructured":"Zhang J, et al. Phase I trial of a novel anti-HER2 antibody-drug conjugate, ARX788, for the treatment of HER2-positive metastatic breast cancer. Clin Cancer Res. 2022. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-0456.","journal-title":"Clin Cancer Res"},{"key":"1705_CR127","doi-asserted-by":"publisher","first-page":"S1288","DOI":"10.1016\/j.annonc.2021.08.2088","volume":"32","author":"C Saura Manich","year":"2021","unstructured":"Saura Manich C, et al. LBA15 Primary outcome of the phase III SYD985002\/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician\u2019s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer. Ann Oncol. 2021;32:S1288. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.2088.","journal-title":"Ann Oncol"},{"key":"1705_CR128","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/s1470-2045(19)30328-6","volume":"20","author":"UT Banerji","year":"2019","unstructured":"Banerji UT, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lanct Oncol. 2019;20:1124\u201335. https:\/\/doi.org\/10.1016\/s1470-2045(19)30328-6.","journal-title":"Lanct Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01705-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-024-01705-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-024-01705-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T07:05:58Z","timestamp":1735283158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-024-01705-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1705"],"URL":"https:\/\/doi.org\/10.1007\/s12672-024-01705-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to the publication of this work in Discover Oncology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"843"}}